This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer compr
This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection.
대표청구항▼
1. A composition comprising: (a) a complement-activating antibody, and(b) a β-(1,3)-glucan in an amount effective to enhance the anti-tumor effect of said antibody,wherein said antibody and said glucan alone has little or no effect on cancer, and wherein said glucan has a molecular weight from about
1. A composition comprising: (a) a complement-activating antibody, and(b) a β-(1,3)-glucan in an amount effective to enhance the anti-tumor effect of said antibody,wherein said antibody and said glucan alone has little or no effect on cancer, and wherein said glucan has a molecular weight from about 40,000 to about 359,000 Daltons. 2. The composition of claim 1, wherein said antibody is a monoclonal antibody. 3. The composition of claim 1, wherein said antibody binds to cancer cells expressing CD20, HER2, EGFR, GD2 or GD3. 4. The composition of claim 1, wherein said cancer is selected from the group consisting of neuroblastoma, melanoma, non-Hodgkin's lymphoma, breast cancer, Epstein-Barr related lymphoma, Hodgkin's lymphoma and epidermoid carcinoma. 5. A composition comprising: (a) a complement-activating antibody, and(b) a β-(1,3)-glucan in an amount effective to enhance the anti-tumor effect of said antibody,wherein said antibody and said glucan alone has little or no effect on cancer, and wherein said glucan is obtained from oat, wheat, moss or yeast. 6. The composition of claim 5, wherein said antibody is a monoclonal antibody. 7. The composition of claim 5, wherein said antibody binds to cancer cells expressing CD20, HER2, EGFR, GD2 or GD3. 8. The composition of claim 5, wherein said cancer is selected from the group consisting of neuroblastoma, melanoma, non-Hodgkin's lymphoma, breast cancer, Epstein-Barr related lymphoma, Hodgkin's lymphoma and epidermoid carcinoma.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (49)
Klein Barbara K., .beta.-D-glucan topical composition.
Nikl Libor H. (Port Coquitlam CAX) Allbright Lawrence J. (Burnaby CAX), Composition and method to enhance the efficacy of a fish vaccine and to stimulate the immune system of fish.
Jamas Spiros ; Easson ; Jr. D. Davidson ; Ostroff Gary R., Enhancement of non-specific immune defenses by administration of underivatized, aqueous soluble glucans.
Bondeson Anders (Gothenburg SEX) Isaak Bernhard (Lausanne CHX) Perrenoud Andre (Nyon CHX) Tran Minh Q. (Lausanne CHX), High-performance gyrotron for production of electromagnetic millimeter or submillimeter waves.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is a.
Cheever, Martin A.; Disis, Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated.
Lane H. Clifford (Bethesda MD) Kovacs Joseph A. (Potomac MD) Fauci Anthony S. (Washington DC), Immunologic enhancement with intermittent interleukin-2 therapy.
Jamas Spiros (Boston MA) Easson ; Jr. D. Davidson (Shrewsbury MA) Ostroff Gary R. (Worcester MA), Method for immune system activation by administration of a b
상세보기
Jamas Spiros (Boston MA) Easson ; Jr. D. Davidson (Shrewsbury MA) Ostroff Gary R. (Worcester MA), Method for producing neutral glucans for pharmaceutical applications.
Williams David L. (River Ridge LA) Browder I. William (New Orleans LA) DiLuzio ; deceased Nicholas R. (late of Gretna LA by Nicholas M. DiLuzio ; legal representative), Methods and compositions for prophylactic and therapeutic treatment of infections.
Williams David L. (River Ridge LA) Browder I. William (New Orleans LA) Diluzio ; deceased Nicholas R. (late of Gretna LA by Nicholas M. Diluzio ; legal representative), Methods and compositions for prophylactic and therapeutic treatment of infections.
Brandt Michael (Iffeldorf DEX) Endl Josef (Weilheim DEX) Jungfer Herbert (Starnberg DEX) Albert Winfried (Eberfing DEX), Monoclonal antibodies against melanoma.
Schlessinger Joseph ; Givol David,ILX ; Bellot Francoise,FRX ; Kris Richard ; Ricca George A. ; Cheadle Christopher ; South Victoria J., Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same.
Chatterjee Malaya ; Foon Kenneth A. ; Chatterjee Sunil K., Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma.
Robbins Ernest A. (High Ridge MO) Seeley Robert D. (Crestwood MO), Process for the prevention and reduction of elevated blood cholesterol and triglycerides levels.
Williams David L. (River Ridge LA) Browder I. William (New Orleans LA) DiLuzio ; deceased Nicholas R. (late of New Orleans LA by Nicholas M. DiLuzio ; legal representative), Soluble phosphorylated glucan: methods and compositions for treatment of neoplastic diseases.
Donzis Byron A. (#18 W. Rivercrest Houston TX 77042), Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional u.
Donzis Byron A. (#18 W. Rivercrest Houston TX 77042), Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional u.
Anderson Darrell R. ; Hanna Nabil ; Leonard John E. ; Newman Roland A. ; Reff Mitchell E. ; Rastetter William H., Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen.
Jamas Spiros (Boston MA) Easson ; Jr. D. Davidson (Shrewsbury MA) Ostroff Gary R. (Worcester MA), Use of aqueous soluble glucan preparations to stimulate platelet production.
Jamas Spiros ; Easson ; Jr. D. Davidson ; Ostroff Gary R., Uses for underivatized, aqueous soluble .beta.(1-3) glucan and compositions comprising same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.